Q-omics provides the consensus-scored SNORA70H profile across patient tissues and cancer cell-line models. SNORA70H expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SNORA70H is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, SNORA70H RNA expression shows 5,916 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, BRCA, and STAD as cancer lineages where SNORA70H shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA70H — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA70H survival associations across molecular data types. SNORA70H RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA70H RNA expression–survival associations across cancer types. High SNORA70H expression shows unfavorable associations in ACC, THCA, LIHC, COAD and GBM, but favorable associations in BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SNORA70H RNA expression.
This table summarizes SNORA70H tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA70H. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA70H shows higher tumor expression in BRCA, BLCA and KIRC. The BRCA box plot shows higher SNORA70H RNA expression in tumor versus normal tissue (log2 FC = +0.099, t-test p = .019).
This table shows molecular features associated with SNORA70H in patient tissues and cancer cell lines. In patient samples, SNORA70H shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
